JPWO2020197502A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020197502A5 JPWO2020197502A5 JP2021556845A JP2021556845A JPWO2020197502A5 JP WO2020197502 A5 JPWO2020197502 A5 JP WO2020197502A5 JP 2021556845 A JP2021556845 A JP 2021556845A JP 2021556845 A JP2021556845 A JP 2021556845A JP WO2020197502 A5 JPWO2020197502 A5 JP WO2020197502A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- antibody
- antigen
- binding fragment
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 25
- 229940124597 therapeutic agent Drugs 0.000 claims 25
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 14
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 206010016654 Fibrosis Diseases 0.000 claims 5
- 230000004761 fibrosis Effects 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 101100024019 Mus musculus Mosmo gene Proteins 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 241001553178 Arachis glabrata Species 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000001708 Dupuytren contracture Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 1
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 235000020232 peanut Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003285 pharmacodynamic effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201902713S | 2019-03-26 | ||
| SG10201902713S | 2019-03-26 | ||
| SG10201905063R | 2019-06-03 | ||
| SG10201905063R | 2019-06-03 | ||
| SG10201907597W | 2019-08-16 | ||
| SG10201907597W | 2019-08-16 | ||
| PCT/SG2020/050170 WO2020197502A1 (en) | 2019-03-26 | 2020-03-26 | Treatment employing anti-il-13r antibody or binding fragment thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022528324A JP2022528324A (ja) | 2022-06-10 |
| JPWO2020197502A5 true JPWO2020197502A5 (enExample) | 2023-04-05 |
Family
ID=70228774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556845A Pending JP2022528324A (ja) | 2019-03-26 | 2020-03-26 | 抗ｉｌ１３ｒ抗体またはその結合フラグメントを用いた治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210277131A1 (enExample) |
| EP (1) | EP3947457A1 (enExample) |
| JP (1) | JP2022528324A (enExample) |
| KR (1) | KR20210143788A (enExample) |
| CN (1) | CN113677708A (enExample) |
| AU (1) | AU2020247175A1 (enExample) |
| CA (1) | CA3134495A1 (enExample) |
| IL (1) | IL286603A (enExample) |
| SG (1) | SG11202109545VA (enExample) |
| WO (1) | WO2020197502A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022186773A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION |
| WO2022186772A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
| WO2023048651A1 (en) * | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | Method for treatment of moderate to severe atoptic dematitis |
| WO2023048650A1 (en) * | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
| US20250325475A1 (en) * | 2021-10-29 | 2025-10-23 | Aslan Pharmaceuticals Pte Ltd | Anti-il-13r antibody formulation |
| WO2023075702A1 (en) * | 2021-10-29 | 2023-05-04 | Aslan Pharmaceuticals Pte Ltd | Anti-il-13r antibody formulation |
| WO2023163659A1 (en) * | 2022-02-23 | 2023-08-31 | Aslan Pharmaceuticals Pte Ltd | Glycosylated form of anti-il13r antibody |
| EP4590335A1 (en) * | 2022-08-26 | 2025-07-30 | ASLAN Pharmaceuticals Pte Ltd | High concentration anti-il13r antibody formulation |
| WO2025095864A1 (en) * | 2023-11-02 | 2025-05-08 | Aslan Pharmaceuticals Pte Ltd | Treatment |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| JP4224135B2 (ja) | 1995-10-23 | 2009-02-12 | ズィナイス セラピューティックス ピーティーワイ．エルティーディー． | 新規なヘモポエチン受容体およびそれをコードする遺伝子配列 |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| AU2002361122A1 (en) | 2001-11-27 | 2003-06-10 | Mochida Pharmaceutical Co., Ltd. | ANTI-IL13 RECEPTOR Alpha1 NEUTRALIZING ANTIBODY |
| WO2003080675A2 (en) | 2002-03-22 | 2003-10-02 | Amrad Operations Pty Ltd | MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13Rα1) |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| JP2007536898A (ja) | 2003-07-01 | 2007-12-20 | セルテック アール アンド ディ リミテッド | 修飾抗体Ｆａｂフラグメント |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| AU2007319604B2 (en) | 2006-10-19 | 2011-03-24 | Csl Limited | High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
| EP2530090A3 (en) * | 2006-10-19 | 2013-01-23 | CSL Limited | Anti-IL-13R alpha 1 antibodies and their uses thereof |
| RU2009140134A (ru) * | 2007-04-23 | 2011-05-27 | Вайет (Us) | Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений |
| CN102164965B (zh) | 2008-09-26 | 2016-03-30 | Ucb医药有限公司 | 生物产品 |
| US20120121580A1 (en) * | 2009-07-28 | 2012-05-17 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| WO2016109822A1 (en) * | 2014-12-31 | 2016-07-07 | Novelmed Therapeutics, Inc. | Formulation of aglycosylated therapeutic antibodies |
| US20200165347A1 (en) * | 2017-06-30 | 2020-05-28 | Aslan Pharmaceuticals Pte Ltd | Method of treatment using il-13r antibody |
-
2020
- 2020-03-26 AU AU2020247175A patent/AU2020247175A1/en active Pending
- 2020-03-26 US US17/272,243 patent/US20210277131A1/en active Pending
- 2020-03-26 CA CA3134495A patent/CA3134495A1/en active Pending
- 2020-03-26 SG SG11202109545V patent/SG11202109545VA/en unknown
- 2020-03-26 EP EP20717992.0A patent/EP3947457A1/en active Pending
- 2020-03-26 KR KR1020217032020A patent/KR20210143788A/ko active Pending
- 2020-03-26 CN CN202080022235.4A patent/CN113677708A/zh active Pending
- 2020-03-26 WO PCT/SG2020/050170 patent/WO2020197502A1/en not_active Ceased
- 2020-03-26 JP JP2021556845A patent/JP2022528324A/ja active Pending
-
2021
- 2021-09-22 IL IL286603A patent/IL286603A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7286595B2 (ja) | 抗体製剤 | |
| US20240417455A1 (en) | Treatment for rheumatoid arthritis | |
| Van Dyck | Anti-amyloid-β monoclonal antibodies for Alzheimer’s disease: pitfalls and promise | |
| JP2022120009A (ja) | ベンラリツマブを使用して喘息の増悪率を低減する方法 | |
| JPWO2020197502A5 (enExample) | ||
| JP2016512262A (ja) | 血管炎の処置におけるレボセチリジン及びモンテルカストの使用 | |
| Markatseli et al. | Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study | |
| US20220127346A1 (en) | Methods of Safe Administration of Anti-Tau Antibody | |
| AU2015382376B2 (en) | Cenicriviroc for the treatment of fibrosis | |
| RU2006113701A (ru) | Лечение респираторных заболеваний антителами против рецептора il-2 | |
| JP2007506681A5 (enExample) | ||
| AU2023343549A1 (en) | Antibodies, compositions, and methods of treatment | |
| CN113924099A (zh) | 针对免疫球蛋白轻链的单克隆抗体与抗体产生细胞和其他免疫细胞上的cd38细胞膜分子的组合治疗al淀粉样变性 | |
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| Zhang et al. | Efficacy and Safety of Dupilumab in Patients From China With Persistent Asthma: A Subgroup Analysis of a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study | |
| US20250042985A1 (en) | Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp) | |
| Mittal et al. | Monica S. Tandon, Ankit Sharma | |
| CA2884124C (en) | Treatment for rheumatoid arthritis | |
| Chen et al. | A Phase I, Randomized, Observer-Blinded, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers | |
| JPWO2021202084A5 (enExample) | ||
| JP2023170339A (ja) | 拡張型心筋症を処置または予防するための医薬組成物 | |
| JPWO2020223435A5 (enExample) | ||
| WO2004098598A1 (en) | COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST | |
| JPWO2022038261A5 (enExample) | ||
| JPWO2023075700A5 (enExample) |